Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
You may also be interested in...
Cipla, which has long-standing experience in antibiotic development in India, strikes alliance with US firm SIGA Technologies. The partners are targeting novel antibacterials, especially against biothreats, and expect to cater to US agency BARDA, among others.
Wockhardt has received QIDP designation in the US for its once-daily zidebactam-based combination antibiotic WCK 6777, taking to six its portfolio products with the status. But unless the FDA gives a clean sheet to the company’s major manufacturing units, this won't help US revenues
India’s Wockhardt has announced its first profit in three years and says a restructuring plan will be carried out soon.